Anti-HER3 Antibody Drug Conjugate Patent by Beijing Sinotau Bio-Pharma
Summary
EPO published patent application EP4355787A1 for Anti-HER3 antibody drug conjugate compositions and methods by Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. The patent covers ADC technology targeting HER3 for cancer treatment with designated states spanning major European jurisdictions. Inventors include Zhong Xiaoyan, Li Zhe, and Zhu Jie.
What changed
EPO published patent application EP4355787A1 for Anti-HER3 antibody drug conjugate (ADC) compositions and their therapeutic use. The patent covers antibodies targeting HER3 and linked cytotoxic agents for treating cancer and immune disorders.
Pharmaceutical and biotech companies developing ADC therapeutics or HER3-targeted therapies should review this patent for potential freedom-to-operate concerns in European markets. Competitors may need to design-around strategies or explore licensing arrangements with Beijing Sinotau.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTI-HER3 ANTIBODY, ANTIBODY DRUG CONJUGATE CONTAINING THE SAME, AND USE THEREOF
Publication EP4355787A1 Kind: A1 Apr 08, 2026
Applicants
Beijing Sinotau Bio-Pharmaceuticals
Technology Co., Ltd.
Inventors
ZHONG, Xiaoyan, LI, Zhe, ZHU, Jie
IPC Classifications
C07K 16/32 20060101AFI20250326BHEP C07K 16/28 20060101ALI20250326BHEP A61K 39/395 20060101ALI20250326BHEP A61K 39/00 20060101ALI20250326BHEP C12N 15/13 20060101ALI20250326BHEP C12P 21/08 20060101ALI20250326BHEP A61P 35/00 20060101ALI20250326BHEP A61P 37/06 20060101ALI20250326BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.